Showcases Stock ranks Forex

Atea Pharmaceuticals Inc (AVIR)
8.59  -0.2 (-2.28%) 08-08 16:00
Open: 8.9 Pre. Close: 8.79
High: 8.9158 Low: 8.59
Volume: 484,294 Market Cap: 715M
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 8.941 - 8.985 8.985 - 9.021
Low: 8.47 - 8.529 8.529 - 8.577
Close: 8.508 - 8.597 8.597 - 8.668
Stock Technical Analysis
Target: Six months: 10.51
One year: 12.28
Support: Support1: 8.02
Support2: 7.42
Resistance: Resistance1: 9.00
Resistance2: 10.51
Pivot: 8.28
Moving Averages: MA(5): 8.50
MA(20): 8.25
MA(100): 7.21
MA(250): 12.13
MACD: MACD(12,26): 0.25
Signal(12,26,9): 0.23
%K %D: %K(14,3): 78.17
%D(3): 77.68
RSI: RSI(14): 61.10
52-Week: High: 46.91
Low: 5.31
Change(%): -69.2
Average Vol(K): 3-Month: 645
10-Days: 328
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.

[ AVIR ] has closed below upper band by 13.2%. Bollinger Bands are 48.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend.
Stock chart
Stock News
Mon, 08 Aug 2022
$AVIR Atea Pharmaceuticals Reports Second Quarter 2022 Financial Results - CML News

Mon, 08 Aug 2022
2022-08-08 | NDAQ:AVIR | Press Release | Atea Pharmaceuticals Inc. - Stockhouse

Mon, 01 Aug 2022
Atea Pharmaceuticals to Host Second Quarter 2022 Financial Results Conference Call on August 8, 2022 - GlobeNewswire

Mon, 11 Jul 2022
Atea Pharmaceuticals Participates in the William Blair Biotech Focus Conference - GlobeNewswire

Sun, 12 Jun 2022
Atea Pharmaceuticals (NASDAQ:AVIR) shareholders have endured a 68% loss from investing in the stock a year ago - Yahoo Movies UK

Thu, 09 Jun 2022
Insiders who purchased Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) stock last year recover some losses which currently stand at US$6.1k - Simply Wall St

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 83.26
Shares Float (M) 69.33
% Held by Insiders 10.52
% Held by Institutions 66.76
Shares Short (K) 2910
Shares Short Prior Month (K) 2020
Stock Financials
EPS 0.530
Book Value (p.s.) 8.170
Profit Margin 16.96
Operating Margin 22.97
Return on Assets (ttm) 5.3
Return on Equity (ttm) 7.6
Qtrly Rev. Growth
Gross Profit (p.s.) 2.212
Sales Per Share 3.428
EBITDA (p.s.) 0.788
Qtrly Earnings Growth
Operating Cash Flow (M) -129.18
Levered Free Cash Flow (M) -141.79
Stock Valuation
PE Ratio 16.21
PEG Ratio
Price to Book value 1.05
Price to Sales 2.51
Price to Cash Flow -5.54
Stock Dividends
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android